Advancing NSCLC Treatment: Overcoming Challenges in Immune Checkpoint Inhibitor Therapy

8,259
Total downloads
39k
Total views and downloads

Articles

CASE REPORT

Published on 28 Jul 2025

Case Report: Pathologic complete response in a patient with simultaneous diagnoses of resectable NSCLC and myeloid neoplasm with PDGFRA rearrangement treated with concurrent neoadjuvant chemoimmunotherapy and imatinib: translating clinical trial data to real-world practice

Chad B. Sussman
Minal Shah
Kausha Amin
Rachel Fanaroff
Eric Krause
Vu H. Duong
Samuel Rosner

doi 10.3389/fonc.2025.1589126

1,300 views

ORIGINAL RESEARCH

Published on 12 Jun 2025

Prognostic analysis and association of the systemic immune-inflammatory index with immune checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer

Mengyao Cai
Jiangqian Sun
Jingyi Wu
Ya Liu
Yuanyi Huang

doi 10.3389/fonc.2025.1596223

1,363 views
1 citation

ORIGINAL RESEARCH

Published on 12 Jun 2025

Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study

Song Guan
Yu Wang
Qing Liu
Meng Yan
Kai Ren
Jun Wang
Nan Bi
Lujun Zhao

doi 10.3389/fimmu.2025.1591134

2,173 views
1 citation

CASE REPORT

Published on 04 Jun 2025

Treatment strategies for rapid recurrence and progression after surgery for stage I pulmonary pleomorphic carcinoma: a case report and literature review

Jing Zhang
Wenji Xiong
Hong Wang
Lemeng Sun
Chen Chen
Xueru Sun
Xiuyue Man
Lei Yang
Zhihong Li

doi 10.3389/fimmu.2025.1547872

2,056 views
1 citation

ORIGINAL RESEARCH

Published on 04 Jun 2025

First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis

Lijuan Chen
Jie Liu
Junfeng Lu
Xiufeng Hu
Erjing An
Yanqiu Zhao

doi 10.3389/fonc.2025.1533048

1,830 views

CASE REPORT

Published on 30 Apr 2025

Acquired ROS1 fusion and iruplinalkib response in advanced NSCLC after multiple lines of systematic therapy: a case report

Jiarui Liu
Zhichao Jiao
Jun Zhou
Yuan Yuan
Qiguang Li
Wei Zhou
Shuai Zhang
Shuping Yang

doi 10.3389/fonc.2025.1571512

1,826 views

SYSTEMATIC REVIEW

Published on 08 Apr 2025

Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis

Hong Huang
Pengchen Bao
Hongyu Jin
Wenyang Li
Hui Shen
Zhen Qin
Ying Pan
Xinming Su
Delei Kong

doi 10.3389/fonc.2025.1493221

3,687 views
1 citation

ORIGINAL RESEARCH

Published on 03 Apr 2025

From COPD to cancer: indacaterol’s unexpected role in combating NSCLC

Chenghao Liu
Jiaqi Huang
Pengjie Cai
Min Jiang
Honglei Chen

doi 10.3389/fphar.2025.1579126

2,029 views
1 citation

MINI REVIEW

Published on 21 Mar 2025

The distinct roles of IL-37 and IL-38 in non-small cell lung carcinoma and their clinical implications

Jiwei Zhang
Steven G. Wise
Shunqing Zuo
Shisan Bao
Xufeng Zhang

doi 10.3389/fimmu.2025.1564357

3,129 views
4 citations

METHODS

Published on 17 Mar 2025

Association between CONUT scores and survival outcomes in patients with non-small cell lung cancer: meta-analysis from 4973 Asian cases

Tao Xie
Zhiwei Dong
Chunlin Wu
Qian Ding
Wenhao Zhan
Shumei Fu
Bihang Zhang
Ning Tian

doi 10.3389/fonc.2025.1522368

1,379 views
2 citations

CASE REPORT

Published on 06 Mar 2025

Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report

Jie Zhu
Wen-jie Wang

doi 10.3389/fonc.2025.1498701

1,730 views
3 citations

ORIGINAL RESEARCH

Published on 20 Feb 2025

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

Grégoire Justeau
Christos Chouaid
Didier Debieuvre
Clarisse Audigier-Valette
Xavier Quantin
Hervé Léna
Lise Bosquet
Nicolas Girard
Minouk J. Schoemaker
6 more
Maurice Pérol

doi 10.3389/fonc.2025.1526931

3,343 views
1 citation

Share on

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Other participating journals

Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- 5.9 impact factor
- 10.8 citescore
Frontiers in Oncology
- Cancer Immunity and Immunotherapy
- Pharmacology of Anti-Cancer Drugs
- 3.3 impact factor
- 6.9 citescore

Impact

39kTopic views
29kArticle views
8,259Article downloads

View impact

Articles

Case Report: Pathologic complete response in a patient with simultaneous diagnoses of resectable NSCLC and myeloid neoplasm with PDGFRA rearrangement treated with concurrent neoadjuvant chemoimmunotherapy and imatinib: translating clinical trial data to real-world practice

Prognostic analysis and association of the systemic immune-inflammatory index with immune checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer

Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study

Treatment strategies for rapid recurrence and progression after surgery for stage I pulmonary pleomorphic carcinoma: a case report and literature review

First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis

Acquired ROS1 fusion and iruplinalkib response in advanced NSCLC after multiple lines of systematic therapy: a case report

Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis

From COPD to cancer: indacaterol’s unexpected role in combating NSCLC

The distinct roles of IL-37 and IL-38 in non-small cell lung carcinoma and their clinical implications

Association between CONUT scores and survival outcomes in patients with non-small cell lung cancer: meta-analysis from 4973 Asian cases

Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Other participating journals

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Frontiers in Oncology

Cancer Immunity and Immunotherapy

Pharmacology of Anti-Cancer Drugs